M4

Decomposing systemic risk: the roles of contagion and common exposures

Retrieved on: 
Tuesday, April 23, 2024
Tao, CIBC, Tax, RWA, Risk, European Systemic Risk Board, Research Papers in Economics, Contagion, RT, The Big Six, NBC, International, Shock, Observation, Bank of Canada, HTC, European Economic Association, The Washington Post, Great, JPMorgan Chase, Paper, GM, Environment, Political economy, Journal of Financial Economics, COVID-19, Perception, BNS, Website, Silicon, IAT, Cifuentes, Probability, Balance sheet, RAN, Medical classification, Algorithm, Information technology, Quarterly Journal of Economics, LN, Nature, European Journal, Royal Bank of Canada, Technical report, Journal of Political Economy, Equitable Bank, Bankruptcy, RAI, PDF, Private, ECB, Policy, CHS, Supercapacitor, Social science, Journal of Financial Stability, Intelligence (journal), Elsevier, Home, Cambridge University Press, Journal, Springer Science+Business Media, Research, Classification, Regulation, News, EQB, Credit, Literature, AIK, European Central Bank, COVID, SVAR, Section 5, Management science, DRA, M4, VL, National bank, Government, ISSN, BMO, Panel, International Financial Reporting Standards, BIS, FIS, Basel III, Commerce, Scotiabank, C32, Econometric Society, Interbank, Fraud, Section 4, Bank, Schedule, VAR, Section 3, The Journal of Finance, RBC, Volcanic explosivity index, Fire, Wassily Leontief, Financial economics, Metric, Section 2, L14, Central bank, Superintendent, Bank of Montreal, Kronecker, BOC, Lithium, BCBS, Sale, Macroeconomic Dynamics, Christophe, CWB, LBC, NHA, Imperial Bank, Private equity, Quarterly Journal, National Bank of Canada, C51, Canadian Western Bank, Currency crisis, JEL classification codes, Victor Drai, L.1, MFC, Silicon Valley Bank, EB, Laurentian Bank of Canada, Federal, RA1, Series, W0, FEVD, Journal of Econometrics, Aggregate, University, FRB, MB, Financial institution, Element, Health, Book, Angels & Airwaves, Common, OSFI, GFC, Reproduction, K L, Systematic, Housing, G21, Home Capital Group, Communications satellite

Abstract

Key Points: 
    • Abstract
      We evaluate the effects of contagion and common exposure on banks? capital through
      a regression design inspired by the structural VAR literature and derived from the balance
      sheet identity.
    • Contagion can occur through direct exposures, fire sales, and market-based
      sentiment, while common exposures result from portfolio overlaps.
    • First, we document that contagion varies in time, with the highest levels
      around the Great Financial Crisis and lowest levels during the pandemic.
    • Our new framework complements
      traditional stress-tests focused on single institutions by providing a holistic view of systemic risk.
    • While existing literature presents various contagion narratives, empirical findings on
      distress propagation - a precursor to defaults - remain scarce.
    • We decompose systemic risk into three elements: contagion, common exposures, and idiosyncratic risk, all derived from banks? balance sheet identities.
    • The contagion factor encompasses both sentiment- and contractual-based elements, common exposures consider systemic
      aspects, while idiosyncratic risk encapsulates unique bank-specific risk sources.
    • Our empirical analysis of the Canadian banking system reveals the dynamic nature of contagion, with elevated levels observed during the Global Financial Crisis.
    • In conclusion, our model offers a comprehensive lens for policy intervention analysis and
      scenario evaluations on contagion and systemic risk in banking.
    • This
      notion of systemic risk implies two key components: first, systematic risks (e.g., risks related
      to common exposures) and second, contagion (i.e., an initially idiosyncratic problem becoming
      more widespread throughout the financial system) (see Caruana, 2010).
    • In this paper, we decompose systemic risk into three components: contagion, common exposures, and idiosyncratic risk.
    • First, we include contagion in three forms: sentiment-based contagion, contractual-based
      contagion, and price-mediated contagion.
    • In this context,
      portfolio overlaps create common exposures, implying that bigger overlaps make systematic
      shocks more systemic.
    • With the COVID-19 pandemic starting
      in 2020, contagion drops to all time lows, potentially related to strong fiscal and monetary
      supports.
    • That is, our
      structural model provides a framework for analyzing the impact of policy interventions and
      scenarios on different levels of contagion and systemic risk in the banking system.
    • This provides a complementary approach to
      seminal papers that took a structural approach to contagion, such as DebtRank Battiston et al.
    • More generally, the literature on networks and systemic risk started with Allen and Gale
      (2001) and Eisenberg and Noe (2001).
    • The matrix is structured as follows:
      1

      In our model, we do not distinguish between interbank liabilities and other types of liabilities.

    • In other words, we can and aim to estimate different degrees
      of contagion per asset class, i.e., potentially distinct parameters ?Ga .
    • For that, we build three major
      metrics to check: average contagion, average common exposure, and average idiosyncratic risk.
    • N i j

      et ,
      Further, we define the (N ?K) common exposure matrix as Commt = [A

      (20)

      et ]diag (?C
      ?L

      such that average common exposure reads,
      average common exposure =

      1 XX
      Commik,t .

    • N i j

      (22)

      20

      ? c ),

      The three metrics?average contagion, average common exposure, and average idiosyncratic risk?provide a comprehensive framework for understanding banking dynamics.

    • Figure 4 depicts the average level of risks per systemic risk channel: contagion risk, common exposure, and idiosyncratic risk.
    • Figure 4: Average levels of contagion (Equation (20)), common exposure (Equation (21)), and idiosyncratic risk
      (Equation (22)).
    • The market-based contagion is the contagion due to
      investors? sentiment, and the network is an estimate FEVD on volatility data.
    • For most of
      the sample, we find that contagion had a bigger impact on the variance than common exposures.

Draft revised Heads of Medicines Agency / European Medicines Agency guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application dossier

Retrieved on: 
Thursday, April 18, 2024
Steps, Union, Patient, CTD, Syndrome, CCI, Local, Disclosure, Toxicity, Process validation, MAH, Clinical trial, IP, RMP, Pharmacovigilance, Cell, Legislation, Annex, Trial of the century, Escherichia coli, Safety, Pediatrics, INTRODUCTION, Documentation, Prevalence, Vital signs, Tablet, Design, Transparency, Conclusion, Pip, Analysis, European Parliament, INN, Record, Quality, Generic, Biology, CMO, Genotoxicity, Composition, CTIS, Uncontrolled, Health care, European Medicines Agency, Prejudice, Committee, Policy, HCP, Animal, Characterization, Cell bank, Fertility, IRB, CMOS, Risk management, Private law, European Pharmacopoeia, Telephone, Research, Good, Data Protection Directive, Ampere-hour, IEC, QP, Human, Personal data, Labelling, Bibliography, Figure, MAA, R4, Institutional review board, Elucidation, Marketing, M4, ChromeOS, Contract research organization, Mental, Impairment, Toxicokinetics, NCA, Independent, Metabolite, Drug, Risk, Metabolism, GMO, Organ, EMA, Common Technical Document, General Data Protection Regulation, Confidentiality, PPD, PI, Language, DRUG, Privacy, Result, Claimed, Medication, Comparison, Ethics, Drive, PD, Narrative, EEA, Developmental toxicity, Saccharomyces cerevisiae, Pharmacopoeia, PIP, MCB, HMA, Physical chemistry, Midol, Particle size, Council, GCP, European Economic Area, Draft, Fermentation, Overview, Justification, Control, Dicarboxylic acid, Pharmacology, WCB, Expert, Immunogenicity, Data, Study, Publication, European, ICH, Element, Analytical procedures (finance auditing), Name, Common, Guideline, Exceptional circumstances, ID, Liver, Chin Na, Toxicology, Protein primary structure, Immunosuppressive drug, Vaccine

See websites for contact details

Key Points: 
    • See websites for contact details
      Heads of Medicines Agencies www.hma.eu
      European Medicines Agency www.ema.europa.eu

      11

      Table of contents

      12

      Abbreviations .............................................................................................. 3

      13

      Definitions ................................................................................................... 4

      14

      1.

    • redaction, masking,

      68

      hiding) in such a manner that the recipient can no longer attribute the resulting information to a data

      69

      subject and make it identifiable.

    • 81

      Contract Manufacturing Organisation (CMO): shall mean an arrangement under which a

      82

      manufacturer provides upstream manufacturing services under contract on behalf of third-party

      83

      pharmaceutical companies.

    • 94

      Protected Personal Data (PPD): shall mean any personal data which should be protected from

      95

      disclosure.

    • ?Finalised? shall mean that the marketing

      102

      authorisation (MA) has been granted or refused or that the MAA has been withdrawn.

    • The application of the general principles laid down in this guidance is without prejudice to

      106

      national rules on transparency.

    • The guidance should be read in conjunction with the relevant applicable

      107

      legislation and case law on transparency and data protection.

    • 117

      This guidance document is intended to apply to information/documents on medicinal products for

      118

      human use, for which the procedure has been finalised under the national, mutual recognition,

      119

      decentralised and centralised procedures.

    • Third

      124

      parties shall be informed or consulted as needed depending on respective national and European legal

      125

      frameworks.

    • 140

      In the following sections, the agreed principles on PD and CCI are presented, including guidance on

      141

      whether such information can be disclosed.

    • EMA/131365/2024

      Page 5/50

      142

      Any information identified as PD or CCI must be subject to a preliminary review by the EMA/NCA prior

      143

      to the possible disclosure of the information/documents.

    • Principles on the protection of personal data (PD)

      145

      The protection of PD is enshrined in EU legislation; it is a fundamental right of EU citizens.

    • In

      146

      compliance with the applicable European/national legislation, PD should be anonymised in order to

      147

      avoid the disclosure of the document undermining the privacy and integrity of any individual.

    • EMA/NCA applies a risk-based approach to assess which PD elements are to be

      152

      removed from the information/documents in order to limit the risk of re-identification.

    • are included in the MAA dossier because they have a legally

      164

      defined role or responsibility and it is in the public interest to disclose this data.

    • 168

      Applicants are advised that non-essential information (e.g., personal address, personal phone number)

      169

      should not be included in the MAA dossier.

    • The

      183

      confidentiality of records that could identify subjects should be protected, respecting the privacy and

      184

      confidentiality rules in accordance with the applicable regulatory requirement(s).

    • 185

      The applicant remains responsible for compliance with the relevant legislation in cases where such data

      186

      is inadvertently included in the MAA dossier.

    • 188

      EMA/NCA applies a risk-based approach to assess which personal data elements need to be removed

      189

      from the information/documents in order to limit the risk of re-identification.

    • 194

      EMA/NCA applies a risk-based approach to assess which personal data elements need to be removed

      195

      from the information/documents in order to limit the risk of re-identification.

    • 205

      Any proposal to consider information as commercially confidential should be properly justified by the

      206

      owner of the information.

    • In this respect, any reference(s) to the risk of that interest being

      209

      undermined should be foreseeable and not purely hypothetical.

    • 210

      Information that is already in the public domain is not considered to be commercially confidential.

    • Information on the Quality and Manufacturing of medicines

      226

      A general principle regarding quality and manufacturing information is that detailed information could

      227

      be considered commercially confidential but general information should be disclosed.

    • 234

      In general, and if not in the public domain, the names of manufacturers or suppliers of the active

      235

      substance or the excipients are considered commercially confidential.

    • 248

      A general description of the type of test methods used and the appropriateness of the specification is

      249

      not commercially confidential.

    • General information on the fermentation and purification process

      259

      is not commercially confidential, although details including operating parameters and specific material

      260

      requirements are commercially confidential.

    • 273

      A general description of the type of test methods used and the appropriateness of the specification is

      274

      not commercially confidential.

    • In general, the data included in clinical trial study reports is considered to be data that can be

      283

      disclosed once PD has been anonymised.

    • 338

      In each module, a non-exhaustive list of information that may be considered protected personal data (PPD) or commercially confidential information

      332
      333

      339

      (CCI) is included.

    • ?

      Direct contact details such as telephone

      Therefore, please refer to the appropriate sub-

      number, fax number, email, postal address,

      modules hereafter for guidance.

    • ?

      Information that may reveal strategic
      (contractual) agreements

      ?

      Any quality information on the clinical batches

      principal investigator

      that might be included here (such as e.g.

    • ?

      Information that may reveal strategic
      (contractual) agreements

      principal investigator

      Study Reports
      5.3.3.3

      as the evaluation of new formulation, innovative

      number, fax number, email, postal

      Paediatric Development Plan (PIP), etc.

    • This may include taking into

      More Than One Study
      5.3.5.4

      Other Clinical Study Reports

      5.3.6

      Reports of Post-Marketing
      Experience

      5.3.7

      Direct identifiers such as name,
      signature, contact details, etc.

LG'S COMMITMENT TO INNOVATION IS RECOGNIZED WITH NUMEROUS AWARDS AT CES 2024

Retrieved on: 
Thursday, January 25, 2024

Named as a winner of Reviewed's Accessibility Awards for CES 2024 – LG's Universal UP Kit – a collection of innovative home appliance accessories and add-ons embracing universal design has been crafted to enhance usability for individuals facing physical challenges.

Key Points: 
  • Named as a winner of Reviewed's Accessibility Awards for CES 2024 – LG's Universal UP Kit – a collection of innovative home appliance accessories and add-ons embracing universal design has been crafted to enhance usability for individuals facing physical challenges.
  • It was also recognized in Apartment Therapy's Best Home Design Products from CES 2024.
  • From the Consumer Technology Association's (CTA) CES Innovation Award program alone, LG won 34 CES Innovation Awards including two Best of Innovation Awards given to the LG 4K Transparent OLED T and the 83-inch 4K OLED Zero Connect TV (M4).
  • Highlights from LG's over 200 awards and recognitions earned at CES 2024 include:
    Gear Patrol: Coolest TVs and Monitors Revealed at CES 2024 – LG OLED evo G4, C4, and OLED B4
    Laptop Mag: Best of CES 2024 – Best 2-in-1: LG gram Pro 2-in-1
    For more information on LG's CES 2024 awards and honors and additional information about LG's products announced at CES, please visit LG Newsroom .

LG's Commitment to Innovation is Recognized with Numerous Awards at CES 2024

Retrieved on: 
Thursday, January 25, 2024

ENGLEWOOD CLIFFS, N.J., Jan. 24, 2024 /PRNewswire/ -- At this year's CES®, LG was honored with more than 200 awards and recognitions for a wide range of innovations and technologies across the home appliance, home entertainment and B2B categories.

Key Points: 
  • It was also recognized in Apartment Therapy's Best Home Design Products from CES 2024.
  • From the Consumer Technology Association's (CTA) CES Innovation Award program alone, LG won 34 CES Innovation Awards including two Best of Innovation Awards given to the LG 4K Transparent OLED T and the 83-inch 4K OLED Zero Connect TV (M4).
  • Highlights from LG's over 200 awards and recognitions earned at CES 2024 include:
    Gear Patrol: Coolest TVs and Monitors Revealed at CES 2024 – LG OLED evo G4, C4 and B4
    Laptop Mag: Best of CES 2024 – Best 2-in-1: LG gram Pro 2-in-1
    For more information on LG's CES 2024 awards and honors and additional information about LG's products announced at CES, please visit LG Newsroom .
  • 1 60% more energy efficient drying - efficiency rating as compared to the requirements for ENERGY STAR® qualification for standard electric dryers.

Italy Compact Construction Equipment Market Assessment 2023-2029: Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Lead with Strong Market Share and Diverse Equipment Offers

Retrieved on: 
Tuesday, January 9, 2024

The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.

Key Points: 
  • The Italy compact construction equipment market is expected to grow at a CAGR of 4.89% from 2022 to 2029.
  • In addition, the growth in renovation and road construction projects is expected to drive the demand for compact earthmoving equipment in the Italy compact construction equipment market.
  • Caterpillar, Volvo CE, Komatsu, JCB, CNH Industrial, SANY, and Hitachi Construction Machinery are front runners in the Italy compact construction equipment market.
  • Compact forklifts accounted for the Italy compact construction equipment market's largest market in 2022.

Ostin Technology Group Announces Participation at CES 2024, the Premier Global Technology Trade Show

Retrieved on: 
Thursday, January 4, 2024

The Company’s CES 2024 booth is at 23030, Central Hall in Las Vegas Convention Center.

Key Points: 
  • The Company’s CES 2024 booth is at 23030, Central Hall in Las Vegas Convention Center.
  • As a company committed to pushing the boundaries of technology and driving industry advancements, the Company values the opportunities that CES 2024 will provide.
  • Visitors are welcomed to try out the products to personally experience the unique design, advanced technology, and practicality of the products.
  • Their advanced health tracking features provide real-time monitoring of users' heart rate, sleep quality, physical activity, and more.

LG UNVEILS LATEST OLED EVO TVS AT THE FOREFRONT OF INNOVATION AND EVOLUTION

Retrieved on: 
Wednesday, January 3, 2024

ENGLEWOOD CLIFFS, N.J., Jan. 3, 2024 /PRNewswire/ -- LG Electronics (LG) is introducing the company's 2024 OLED TV lineup, taking home entertainment experience to a new level. Powered by the company's latest AI processor with 4-fold higher AI performance, these new additions to the OLED lineup deliver unparalleled viewing experiences with even more vibrant, lifelike picture quality. U.S. pricing and availability will be announced at a later date.

Key Points: 
  • LG is introducing the all-new and expanded OLED TV lineup for 2024 with a cutting-edge AI-powered processor; developed by LG, exclusively designed for OLED TVs.
  • Notably the LG SIGNATURE OLED M4 and LG OLED G4 TVs are equipped with the new α (Alpha) 11 AI processor, which effectively enhances picture and audio quality.
  • LG's newest OLED TVs come with upgraded AI upscaling utilizing precise pixel-level image analysis, to effectively sharpen objects and backgrounds that may appear blurry.
  • This all culminates with the LG SIGNATURE OLED M4, LG's wireless OLED TV.

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Retrieved on: 
Friday, December 22, 2023

The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • ET
    PRINCETON, N.J. & BOSTON -- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Retrieved on: 
Friday, December 22, 2023

Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors.
  • “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.